Record Year of Progress for OxC-betaTM Adoption Worldwide
Supply agreement with AB Vista in United States, Brazil and Thailand compliments existing partnerships in Asia and Mexico
Continued positive animal trial results leading to orders, new customer wins and growing recognition from the scientific community
OTTAWA, Ontario, April 08, 2022–(BUSINESS WIRE)–Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, today announced the results of its annual general meeting of shareholders and highlighted the significant progress made in the Corporation’s efforts to drive further adoption of OxC-betaTM worldwide.
At the Company’s…
